Can-Fite BioPharma Ltd. Depreciation Expense on Reclassified Assets
Can-Fite BioPharma Ltd. (CANF) reported Depreciation Expense on Reclassified Assets of $14 for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DepreciationExpenseOnReclassifiedAssets · last filed 2023-03-30
| Period end | Depreciation Expense on Reclassified Assets 12 month | Depreciation Expense on Reclassified Assets 12 month as first filed |
|---|---|---|
| 2022-12-31 | $14.00 20-F · filed 2023-03-30 | |
| 2021-12-31 | $14.00 20-F · filed 2023-03-30 | |
| 2020-12-31 | $12.00 20-F · filed 2023-03-30 | $12.00K 20-F · filed 2021-03-25 |
| 2019-12-31 | $14.00 20-F · filed 2022-03-24 | $14.00K 20-F · filed 2021-03-25 |
| 2018-12-31 | $14.00K 20-F · filed 2021-03-25 |